Enanta Pharmaceuticals (ENTA) Short Interest Ratio & Short Volume → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free ENTA Stock Alerts $12.37 -0.11 (-0.88%) (As of 04/26/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Enanta Pharmaceuticals Short Interest DataCurrent Short Volume2,740,000 sharesPrevious Short Volume2,740,000 sharesChange Vs. Previous MonthNo ChangeDollar Volume Sold Short$44.25 millionShort Interest Ratio / Days to Cover12.0Last Record DateApril 15, 2024Outstanding Shares21,160,000 sharesFloat Size19,650,000 sharesShort Percent of Float13.94%Today's Trading Volume67,161 sharesAverage Trading Volume251,875 sharesToday's Volume Vs. Average27% Short Selling Enanta Pharmaceuticals ? Sign up to receive the latest short interest report for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatENTA Short Interest Over TimeENTA Days to Cover Over TimeENTA Percentage of Float Shorted Over Time Ad Stansberry ResearchMove Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. Enanta Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20242,740,000 shares $44.25 million No Change13.9%12 $16.15 3/31/20242,740,000 shares $47.84 million +13.7%13.9%10.4 $17.46 3/15/20242,410,000 shares $34.25 million +15.3%12.3%9.2 $14.21 2/29/20242,090,000 shares $30.03 million -5.4%10.6%8 $14.37 2/15/20242,210,000 shares $29.30 million +20.1%11.2%8.2 $13.26 1/31/20241,840,000 shares $22.36 million +15.7%9.3%6.5 $12.15 Get the Latest News and Ratings for ENTA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/15/20241,590,000 shares $17.82 million +2.6%8.1%5.4 $11.21 12/31/20231,550,000 shares $14.59 million -13.9%7.9%5.4 $9.41 12/15/20231,800,000 shares $16.81 million +22.5%9.2%6.4 $9.34 11/30/20231,470,000 shares $13.73 million -2.7%7.5%3.4 $9.34 11/15/20231,510,000 shares $13.21 million +12.7%7.7%3.3 $8.75 10/31/20231,340,000 shares $12.09 million +3.9%6.9%3.1 $9.02 10/15/20231,290,000 shares $12.42 million +8.4%6.6%3 $9.63 9/30/20231,190,000 shares $13.29 million -42.0%6.8%2.9 $11.17 9/15/20232,050,000 shares $26.10 million +22.0%10.5%5.2 $12.73 8/31/20231,680,000 shares $24.95 million +16.7%8.6%6 $14.85 8/15/20231,440,000 shares $22.82 million No Change7.4%6.4 $15.85 7/31/20231,440,000 shares $27.32 million +5.9%7.4%6 $18.97 7/15/20231,360,000 shares $26.14 million +14.3%7.0%5.9 $19.22 6/30/20231,190,000 shares $25.47 million +47.3%6.2%5.3 $21.40 6/15/2023808,100 shares $19.54 million +2.3%4.2%3.7 $24.18 5/31/2023789,600 shares $18.54 million +18.2%4.1%3.9 $23.48 5/15/2023667,800 shares $17.28 million -6.4%3.5%3.4 $25.87 4/30/2023713,500 shares $25.36 million -2.4%3.7%3.8 $35.55 4/15/2023730,800 shares $26.70 million +4.8%3.8%4.2 $36.53 3/31/2023697,100 shares $28.19 million -22.6%3.6%3.9 $40.44 3/15/2023900,100 shares $40.06 million +20.0%4.7%5.3 $44.51 2/28/2023750,300 shares $36.39 million -8.4%3.9%4.8 $48.50 2/15/2023819,500 shares $41.12 million -3.8%4.3%5.1 $50.18 1/31/2023851,400 shares $45.45 million +0.4%4.4%5.5 $53.38 1/15/2023847,700 shares $43.62 million -1.6%4.4%5 $51.46 12/30/2022861,500 shares $40.08 million -6.0%4.5%5 $46.52 12/15/2022916,400 shares $40.17 million -11.9%4.8%5.1 $43.84 11/30/20221,040,000 shares $45.54 million +4.2%5.4%5.4 $43.79 11/15/2022998,400 shares $47.14 million -4.0%5.2%4.9 $47.22 10/31/20221,040,000 shares $46.91 million -17.5%5.4%5.1 $45.11 10/15/20221,260,000 shares $59.16 million -2.3%6.5%6 $46.95 9/30/20221,290,000 shares $66.91 million -5.2%6.7%6.4 $51.87 9/15/20221,360,000 shares $78.77 million -8.1%7.0%6.1 $57.92 8/31/20221,480,000 shares $90.10 million -3.3%7.7%6.1 $60.88Move Your Money Before May 1 (Ad)Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. ENTA Short Interest - Frequently Asked Questions What is Enanta Pharmaceuticals' current short interest? Short interest is the volume of Enanta Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of April 15th, traders have sold 2,740,000 shares of ENTA short. 13.94% of Enanta Pharmaceuticals' shares are currently sold short. Learn More on Enanta Pharmaceuticals' current short interest. What is a good short interest ratio for Enanta Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ENTA shares currently have a short interest ratio of 12.0. Learn More on Enanta Pharmaceuticals's short interest ratio. Which institutional investors are shorting Enanta Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Enanta Pharmaceuticals: Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Enanta Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 13.94% of Enanta Pharmaceuticals' floating shares are currently sold short. What is Enanta Pharmaceuticals' float size? Enanta Pharmaceuticals currently has issued a total of 21,160,000 shares. Some of Enanta Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Enanta Pharmaceuticals currently has a public float of 19,650,000 shares. How does Enanta Pharmaceuticals' short interest compare to its competitors? 13.94% of Enanta Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Enanta Pharmaceuticals: RAPT Therapeutics, Inc. (9.14%), Werewolf Therapeutics, Inc. (1.40%), Vanda Pharmaceuticals Inc. (3.80%), ESSA Pharma Inc. (1.74%), Nanobiotix S.A. (0.11%), Inozyme Pharma, Inc. (7.66%), Akebia Therapeutics, Inc. (6.54%), Renovaro Inc. (2.16%), Verrica Pharmaceuticals Inc. (15.09%), Erasca, Inc. (10.56%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Enanta Pharmaceuticals stock? Short selling ENTA is an investing strategy that aims to generate trading profit from Enanta Pharmaceuticals as its price is falling. ENTA shares are trading down $0.11 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Enanta Pharmaceuticals? A short squeeze for Enanta Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ENTA, which in turn drives the price of the stock up even further. How often is Enanta Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ENTA, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: RAPT Therapeutics Short Interest Data Werewolf Therapeutics Short Interest Data Vanda Pharmaceuticals Short Interest Data ESSA Pharma Short Interest Data Nanobiotix Short Interest Data Inozyme Pharma Short Interest Data Akebia Therapeutics Short Interest Data Renovaro Short Interest Data Verrica Pharmaceuticals Short Interest Data Erasca Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ENTA) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry